Skip to main content

Advertisement

SpringerLink
Log in

A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Gaucher disease (GD) is the most prevalent lysosomal storage disease, and bone involvement is the most disabling condition. The aim of the present study was to evaluate bone involvement in adult patients with GD, using an observational cross-sectional study. Patients were evaluated using X-rays, bone densitometry (BMD), trabecular bone score (TBS), magnetic resonance imaging (MRI), and biochemical bone markers. Thirty-two type 1GD patients were included (mean age: 40 ± 16 years). Patients had received velaglucerase for 2.7 ± 1.4 years; 19/32 had been treated previously with imiglucerase. Ninety-four percent of subjects met therapeutic goals for hematological parameters, and eight were splenectomized (SPX). Nineteen patients had irreversible bone lesions (IL), i.e., avascular necrosis, bone infarction, and/or vertebral fractures. MRI showed marrow infiltration in 71% of patients. Patients with IL had higher bone marrow burden than those without (p = 0.001). All SPX patients had IL, a higher prevalence of bone marrow edema (p = 0.02), and lower TBS (p = 0.03) than non-SPX patients. Only 18.7% of patients had abnormal BMD, with no correlation with fractures (FX). TBS values were < 1350 in 53% of patients and tended to be lower in those with FX (p = 0.06). Patients with P1NP in the lower quartile had lower TBS (p = 0.03) than those with P1NP in the higher quartiles. TBS correlated moderately but not significantly with P1NP (r = 0.32) and BMB (r = − 0.44). A high prevalence of IL was documented. Bone quality was more affected than BMD in fracture patients. Low bone formation, active bone marrow infiltration, and splenectomy might be implicated in IL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C et al (2017) A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 18:441

    Article  CAS  PubMed Central  Google Scholar 

  2. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A (2004) New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 25:147–151

    Article  CAS  PubMed  Google Scholar 

  3. Horowitz M, Zimran A (1994) Mutations causing Gaucher disease. Hum Mutat 3:1–11

    Article  CAS  PubMed  Google Scholar 

  4. Drelichman G, Linares A, Villalobos J, Cabello JF, Kerstenetzky M, Kohan RM, Martins AM. (2012) Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease. Medicina 72:273–82

    PubMed  Google Scholar 

  5. Deegan PB, Pavlova E, Tindall J et al (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90:52–60

    Article  CAS  Google Scholar 

  6. Marcucci G, Zimran A, Bembi B et al (2014) Gaucher disease and bone manifestations. Calcif Tissue Int 95:477–494

    Article  CAS  PubMed  Google Scholar 

  7. Giraldo P, Solano V, Pérez-Calvo JI, Giralt M, Rubio-Félix D, Spanish Group on Gaucher disease (2005) Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 14(2):453–462

    Article  PubMed  Google Scholar 

  8. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi M (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75(1):A2–A12

    Article  PubMed  Google Scholar 

  9. Genant HK, Wu CY, van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148

    Article  CAS  PubMed  Google Scholar 

  10. https://www.iscd.org/official-positions/2nd-iscd-pediatric-position-development-conference/

  11. https://www.iscd.org/official-positions/6th-iscd-position-development-conference-adult

  12. Silva BC, Leslie D, Resch H et al (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518–530

    Article  PubMed  Google Scholar 

  13. Maas M, van Kuijk C, Stoker J et al (2003) Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to dixon quantitative chemical shift MR imaging–initial experience. Radiology 229(2):554–561

    Article  PubMed  Google Scholar 

  14. Bondar C, Mucci J, Crivaro A, Ormazabal M, Ceci R, Oliveri B, González D, Rozenfeld P (2017) In vitro osteoclastogenesis from Gaucher patients’ cells correlates with bone mineral density but not with chitotriosidase. Bone 103:262–269

    Article  CAS  PubMed  Google Scholar 

  15. Drelichman G, Fernández Escobar N, Basack N et al (2015) Argentina Gaucher disease consensus update: Argentine group for diagnosis and treatment of Gaucher disease. Hematologia 19:4–51

    Google Scholar 

  16. van Dussen L, Biegstraaten M, Dijkgraaf MGW, Hollak CEM (2014) Modelling Gaucher disease progression: long term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis 9:112

    Article  PubMed  PubMed Central  Google Scholar 

  17. Andrade-Campos M, Valero E, Roca M, Giraldo P (2018) On behalf of the, Spanish group on Gaucher disease: the utility of magnetic resonance imaging for bone involvement in Gaucher disease. Assessing more than bone crises blood cells, Mol Dis 68: 126–134

    Google Scholar 

  18. Kaplan P, Andersson HC, Kacena K, Yee JD (2006) The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 160:603–608

    Article  PubMed  Google Scholar 

  19. Drelichman G, Fernández Escobar N, Basack N et al (2016) Skeletal involvement in Gaucher disease: an observational multicenter study of prognostic factors in the Argentine Gaucher disease patients. Am J Hematol 91:E448–E453

    Article  CAS  PubMed  Google Scholar 

  20. Mikosch P, Hughes D (2010) An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 160:609–624

    Article  PubMed  Google Scholar 

  21. Khan A, Hangartner T, Weinreb NJ et al (2012) Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher registry. J Bone Miner Res 27:1839–1848

    Article  PubMed  Google Scholar 

  22. Melton LJ, Atkinson EJ, Cooper C, O´Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221

    Article  PubMed  Google Scholar 

  23. Harvey N, Dennison E, Cooper C (2013) The epidemiology of osteoporotic fractures. In: Rosen C (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edn. Wiley-Blackell, New Jersey, pp 348–356

    Chapter  Google Scholar 

  24. Crary S, Buchanan G (2009) Vascular complications after splenectomy for hematologic disorders. Blood 114:2861–2868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mucci JM, Rozenfeld P (2015) Pathogenesis of bone alterations in Gaucher disease: the role of immune system. J Immunol. https://doi.org/10.1155/2015/192761

    Article  Google Scholar 

  26. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321):1929–1936

    Article  PubMed  Google Scholar 

  27. Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 26:2762–2769

    Article  PubMed  Google Scholar 

  28. Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi ML, Cooper C et al (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice: a consensus report of a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group. Bone 78:216–224. https://doi.org/10.1016/j.bone.2015.05.016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ulivieri FM, Silva BC, Sardanelli F, Hans D, Bilezikian JP, Caudarella R (2014) Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine 7:435–448

    Article  CAS  Google Scholar 

  30. Baldini M, Casirati G, Ulivieri FM, Cassinerio E, Chalouhi KK, Poggiali E et al (2018) Skeletal involvement in type 1 Gaucher disease: not just bone mineral density. Blood Cells Mol Dis 68:148–152. https://doi.org/10.1016/j.bcmd.2017.06.003

    Article  CAS  PubMed  Google Scholar 

  31. Herrera S, Perez-Lopez J, Molto-Abad M, Guerri-Fernandez G, Cabezudo E, Novelli S et al (2017) Assessment of bone health in patients with type 1 Gaucher disease using impact microindentation. J Bone Miner Res 32:1575–1581

    Article  CAS  PubMed  Google Scholar 

  32. Parisi MS, Mastaglia SR, Bagur A, Goldstein G, Zeni SN, Oliveri B (2008) Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase. Eur J Med Res 13:31–38

    CAS  PubMed  Google Scholar 

  33. van Dussen L, Lips P, Everts VE et al (2011) Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease. J Clin Endocrinol Metab 96:2194–2205

    Article  CAS  PubMed  Google Scholar 

  34. Giuffrida G, Cingari M, Parrinello N et al (2012) Bone turnover markers in patients with type 1 Gaucher disease. Hematol Rep 4:e21. https://doi.org/10.4081/hr.2012.e21

    Article  PubMed  PubMed Central  Google Scholar 

  35. Panicker LM, Srikanth MP, Castro-Gomes T, Miller D, Andrews NW. Feldman RA (2018) Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition. Hum Mol Genet 27:811–822. https://doi.org/10.1093/hmg/ddx442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D et al (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA 107:19473–19478

    Article  PubMed  Google Scholar 

  37. Reed M, Baker RJ, Mehta AB, Hughes D (2013) Enhanced differentiation of osteoclasts from mononuclear precursors in patients with Gaucher disease. Blood Cells Mol Dis 51:185–194

    Article  CAS  PubMed  Google Scholar 

  38. Mucci M, Scian R, De Francesco PN et al (2012) Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-α. Gene 509:51–59. https://doi.org/10.1016/j.gene.2012.07.071

    Article  CAS  PubMed  Google Scholar 

  39. Lai JKC, Robertson PL, Goh C, Szer J (2018) Intraobserver and interobserver variability of the bone marrow burden (BMB) score for the assessment of disease severity in Gaucher disease, possible impact of reporting experience. Blood Cell Mol Dis 68:121–125

    Article  Google Scholar 

  40. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420. https://doi.org/10.1007/s00198-010-1501-1

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the following haematologists who collaborated in the recruitment of the patients: Arizo A, Aznar M, Bolesina M, Fernandez Sasso D., Fernandez V, Fondevila C, Guelbert N, Meschengeiser S, Murieda B, Navarro G, Onelda G, Rocaspana A, Romero Maciel A, Ruiz A., Santini F, Sanchez G, Stivel M, Watman N.

Author information

Authors and Affiliations

  1. Laboratorio de Osteoporosis y Enf. Metabólicas Oseas, INIGEM (UBA-CONICET) Hosp.de Clínicas JSM, Cordoba 2351-Piso 8, 1120, Ciudad Autonoma de Buenos Aires, Argentina

    Beatriz Oliveri

  2. Mautalen Salud e Investigación, Azcuenaga, 1860-Piso 6, 1128, Ciudad Autonoma de Buenos Aires, Argentina

    Diana González

  3. Diagnóstico Maipú, Av. Maipú 1660, Vicente López, 1602, Buenos Aires, Argentina

    Felisa Quiroga & Claudio Silva

  4. IIFP, Universidad Nacional de La Plata, CONICET, Facultad de Ciencias Exactas, Departamento de Ciencias Biologicas, Calle 47 y 115-La Plata, 1900, Buenos Aires, Argentina

    Paula Rozenfeld

Authors
  1. Beatriz Oliveri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana González
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felisa Quiroga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudio Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paula Rozenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OB participated in the study design, acquisition and analysis of data, and drafting and revision of the manuscript. GD participated in the acquisition and analysis of data and drafting and revision of the manuscript. SC and QF participated in acquisition of data, RP participated in acquisition of data and critical review of the manuscript.

Corresponding author

Correspondence to Beatriz Oliveri.

Ethics declarations

Conflict of interest

Beatriz Oliveri, Diana González, and Paula Rozenfeld have received speaking honoraria from Shire; Felisa Quiroga and Claudio Silva declare no conflict of interest.

Human and Animal Rights and Informed Consent

This study was approved by the Ethical Committee of IBYME (Instituto de Biología y Medicina Experimental, Argentina). All patients or their guardians provided written informed consent to participate in this study.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oliveri, B., González, D., Quiroga, F. et al. A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina. Calcif Tissue Int 104, 650–657 (2019). https://doi.org/10.1007/s00223-019-00536-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-019-00536-x

Keywords

Search

Navigation